cnl_21

Epac - Associazione Onlus

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Malattie autoimmuni

Fai una donazione

Sostieni EpaC Onlus

Newsletter EpaC

Aggiornati via email. Iscriviti

Notiziario Epac

Periodico cartaceo. Iscriviti

Sangue Infetto

Visita il sito - legge 210/92

News nuovi farmaci in Inglese

Investigational Triple-DAA Regimen plus Ribavirin Treatment for 12 Weeks Demonstrated High SVR12 Rates in Intent-to-Treat Analysis, - Phase 3 Registrational Program Currently Enrolling

12/11/2012

GILEAD ANNOUNCES 100 PERCENT SUSTAINED VIROLOGIC RESPONSE RATE (SVR4) FOR AN INTERFERON-FREE REGIMEN OF SOFOSBUVIR (GS-7977), GS-5885 AND RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS

12/11/2012

FDA Hepatitis Update - Victrelis (boceprevir) labeling update

05/11/2012

Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study

16/10/2012

A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis c following liver retransplantation

24/08/2012

HCV Update Selected Highlights: key new HCV drugs, timelines & recent news developments

24/08/2012

Use of telaprevir plus peg interferon/ribavirin for null responders post olt with advanced fibrosis/cholestatic hepatitis c

11/06/2012

Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: PROVIDE Study Interim Results

11/05/2012

Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) in HCV G1 Treatment-experienced Patients Achieves Primary Endpoint with Superior Efficacy at Treatment Week 12 Compared to Retreatment with PR

08/05/2012

TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon / ribavirin treatment: Virologic analyses of the ASPIRE trial

08/05/2012

TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial

08/05/2012

GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy

08/05/2012

Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study

08/05/2012

Gilead: Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen

08/05/2012

The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2

08/05/2012

SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2

08/05/2012

Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin

08/05/2012

Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients - press release

08/05/2012

Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial

04/05/2012

A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders

04/05/2012

Pagina: 1 2 3 4 5

© Copyright 2015 - Associazione EpaC Onlus - C.F. 97375600158

Via Col. Tommaso Masala, 42
C/O Parco Altamira - 00148 Roma

Tel. 06.60200566 | Fax 06.60209056
Orari ufficio: 9.00-12.00 e 14.00-17.00

Via Luigi Cadorna, 17/A
20871 Vimercate Monza e Brianza

Tel. 0396083527 | Fax 039 6611523
Orari ufficio: 9.00-12.00 e 14.00-17.00

ACE - Alleanza Contro Epatiti World Hepatitis Alliance ELPA - European Liver Patients Associations